AB0760 Role of oral cyclophosphamide in the treatment of giant cell arteritis. (23rd January 2014)

• Record Type: Journal Article
• Authors: Quartuccio, L.; Maset, M.; De Maglio, G.; Pontarini, E.; Fabris, M.; Mariuzzi, L.; Pizzolitto, S.; Beltrami, C.A.; De Vita, S.
• Is Part Of: Annals of the rheumatic diseases. Volume 71(2012)Supplement 3
• Page Start: 682
• Page End: 682
• Publication Date: 2014-01-23
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2012-eular.760
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Glucocorticoids (GC)-related adverse events greatly contribute to the outcome in giant cell arteritis (GCA). There is limited evidence of the efficacy of some DMARDs as steroid-sparing agents in GCA. CYC may be of value in the treatment of systemic vasculitis, including large vessel arteritis. Objectives: Oral cyclophosphamide (CYC) was investigated as a steroid-sparing agent in GCA. Methods: Nineteen patients treated with CYC were retrospectively analyzed. The patients were 16 females and 3 males, with a mean age at disease onset of 70.11±7.94 years. All patients presented with headache at onset; polymyalgia rheumatica (PMR) was associated to GCA in 13/19 patients; 1/19 presented with upper limb claudication and absent radial pulse. Patients fulfilled at least one of the following 3 characteristics: (a) resistance to GC, i.e., persistence of both symptoms and elevated C reactive protein and/or ESR after induction with 1 mg/kg/day of prednisone given for at least 1 month; (b) disease relapse during high to medium dose of GC therapy (0.3-1 mg kg/day of prednisone); (c) unacceptable risk of GC toxicity, i.e., diabetes mellitus, severe osteoporosis, uncontrolled arterial hypertension, ischemic cardiopathy, cerebrovascular events. Follow-up ranged from 1 month to nearly 9 years after the end of CYC treatment. Results: Patients starting CYC ab initio for unacceptable risk of GC toxicity were 4/19 (group c). Among the remaining 15 patients, 5 patients were refractory to GC (group a), while 10 patients relapsed during steroid tapering (group b). The median dose of CYC was 100 mg/day (range 75-150). Overall, clinical and laboratory efficacy of CYC was observed in 15/19 (78.9%) patients. CYC was administered for more than three months in 10/19 (52, 6%) patients, with response in 9/10. CYC was administered for 3 months in 5/19 (26, 3%) patients, with response in 4/5, and suspension for inefficacy and side effects in the remaining patient. CYC was administered for less than 3 months in 4/19 (21%) patients with efficacy in 2/4. Treatment suspension occurred for inefficacy in 1/4 and for side effects in 3/4 of these cases. The follow-up after the completion of CYC treatment varied from 1 month to 100 months. A follow-up ≥6 months after CYC was available in 13/15 patients, and a follow-up ≥12 months after CYC in 11/15 patients. Remission ≥6 months was registered in 12/13 responders, and remission ≥12 months in 10/11 responders. GC were suspended in 6/15, and they were continued at a dose ≤5 mg/day of prednisone in all the remaining responders. Relapse occurred in 4/15 patients, usually more than 12 months after CYC suspension. Suspension of GC daily dose or reduction ≤5 mg/day of prednisone occurred within the first 6 months of follow-up after the beginning of CYC in 10/15 patients. Ten adverse events were registered in 9 patients, with recovery usually soon after the suspension of CYC or dose reduction. However, one death occurred due to acute hepatitis. Conclusions: CYC may represent an useful option for patients requiring a prolonged medium to high dose GC therapy and at high risk of GC-related side effects. Disclosure of Interest: None Declared